La Jolla Pharmaceutical Company - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for La Jolla Pharmaceutical Company. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

La Jolla Pharmaceutical Company. The Group's principal activity is to conduct research and development of therapeutics for the treatment of certain life-threatening antibody-mediated diseases. The diseases include autoimmune conditions such as systemic lupus erythematosus and antibody-mediated stroke that are caused by abnormal B cell production of antibodies that attach healthy tissues. The current therapies for these autoimmune disorders target the symptoms of the diseases or nonspecifically suppress the normal operation of the immune system. The Group's strategy is to Collaborate with pharmaceutical companies to access their research, drug development, manufacturing, marketing and financial resources. On January 11, 2006, The Group announced that would initiate a multi-dose clinical study of Riquent in lupus patients to evaluate the ability of higher doses of Riquent to further reduce antibodies to double stranded DNA.

Not the Report you are looking for? Click here for more browsing options.

$600/yr | Annual Subscription | Premium Access to more than 150,000 company reports for $600/year**

$59.99/mo | Monthly Subscription | Premium Access to more than 150,000 company reports for $59.99/month**

$39.95 | ALL Reports on this company | Buy all reports for La Jolla Pharma Co

$24.95 | Single Earnings Analysis Report | Buy this La Jolla Pharma Co Earnings Analysis

Set Currency* Argentinian Pesos Australian Dollars Bermudan Dollars Brazilian Reals Canadian Dollars Chilean Pesos Chinese Renmimbi Colombian Pesos Czech Koruni Danish Kroner Dirham Egyptian Pounds Euro Hong Kong Dollars Hungarian Forints Icelandic Kronas Indian Rupees Indonesian Rupiahs Israel Shekels Japanese Yen Jordanian Dinars Korean Won Malaysian Ringgits Mexican Pesos Moroccan Dirhams New Zealand Dollars Norwegian Kroner Pakistan Rupees Peruvian New Sols Philippine Pesos Polish New Zlotys Pounds Sterling Russian Rubles Saudi Riyals Singapore Dollars Slovak Koruni South African Rands Sri Lanka Rupees Swedish Kronor Swiss Francs Taiwanese Dollars Thai Bahts Turkish Liras U.S. Dollars Venezuelan Bolivars Zimbabwe Dollars * If a currency is not selected, the report will be delivered in the local currency of the company ** Premium access limits users to 500 reports per month

Layout and Content of a Typical Report